SNDX SYNDAX PHARMACEUTICALS

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit  or follow the Company on  and .

Syndax Contact

Sharon Klahre 

Syndax Pharmaceuticals, Inc. 



Tel 781.684.9827



EN
04/04/2025

Underlying

SNDXSYNDAX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNDAX PHARMACEUTICALS

 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Reports Third Quarter 2025 Financial Results and Provides Busin...

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update – $45.9 million in total revenue, representing 21% growth over 2Q25 –  – $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand – – $45.8 million Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte; $13.9 million in collaboration revenue reported by Syndax – – Revuforj FDA-approved in R/R NPM1m AML on October 24, 2025 – – $456.1 million in cash, cash equivalents and investments expected to fund the company to profitabi...

11h / 9m 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax to Host ASH Investor Event in Person and via Webcast on Decembe...

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company’s Revufor...

18h / 1m 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axati...

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 – 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting –  – Axatilimab abstracts highlight potential for long-term benefit in R/R chronic GVHD and tolerability of axatilimab with ruxolitinib in newly diagnosed chronic GVHD – NE...

18h / 2m 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Participation in November Investor Conferences

Syndax Announces Participation in November Investor Conferences NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: UBS Global Healthcare Conference 2025 with a fireside chat on Monday, November 10, 2025, at 11:00 a.m. ET.  Guggenheim Second Annual Healthcare Innovation Conference with a fireside ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax to Announce Third Quarter 2025 Financial Results and Host Confe...

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 3, 2025. The live audio webca...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch